APA
RNAC icon

American Portfolios Advisors’s Cartesian Therapeutics RNAC Stock Holding History

American Portfolios Advisors’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		$11.9K Hold
242
– – ﹤0.01% 2452
2022
Q2 		$9.5K Hold
242
– – ﹤0.01% 2591
2022
Q1 		$8.92K Hold
242
– – ﹤0.01% 2737
2021
Q4 		$23.6K Buy
242
+34
+16% +$3.66K ﹤0.01% 2251
2021
Q3 		$26K Buy
208
+41
+25% +$4.95K ﹤0.01% 2142
2021
Q2 		$20.9K Hold
167
– – ﹤0.01% 2202
2021
Q1 		$22.6K Buy
+167
New +$20.7K ﹤0.01% 2001

Other funds holding RNAC

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
ECM
Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return
N
NanoDimension Woodside, California $24.7M AUM 74.01% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

American Portfolios Advisors's RNAC Position: Q3 2022 in Review

American Portfolios Advisors held its Cartesian Therapeutics (RNAC) position steady in Q3 2022 at 242 shares worth $11.9K. The position accounts for ﹤0.01% of the portfolio, ranked #2452.

American Portfolios Advisors first reported a position in RNAC in Q1 2021 and has held it in 7 quarters since. The position peaked at $26K in Q3 2021. 96 funds tracked by Wall St. Rank hold RNAC as of Q3 2022.

  • American Portfolios Advisors held 242 shares of Cartesian Therapeutics worth $11.9K as of Q3 2022.
  • American Portfolios Advisors left its Cartesian Therapeutics share count unchanged in Q3 2022.
  • Cartesian Therapeutics made up ﹤0.01% of American Portfolios Advisors's portfolio in Q3 2022, its #2452 holding.
  • American Portfolios Advisors first reported a position in Cartesian Therapeutics in Q1 2021 and has held it in 7 quarters since.
  • American Portfolios Advisors's Cartesian Therapeutics position peaked at $26K in Q3 2021.
  • 96 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q3 2022.

Based on American Portfolios Advisors's 13F filing for Q3 2022, filed 17 Mar 2023.